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Adverse effects of extracorporeal carbon
dioxide removal (ECCO2R) for acute
respiratory failure: a systematic review
protocol
Zulian Liu, Rui V. Duarte, Sue Bayliss, George Bramley and Carole Cummins*
Abstract
Background: The extracorporeal membrane carbon dioxide removal (ECCO2R) system is primarily designed for
the purpose of removing CO2 from the body for patients with potentially reversible severe acute hypercapnic
respiratory failure or being considered for lung transplantation. Systematic reviews have focused on the
effectiveness of ECCO2R. To the author’s best knowledge, this is the first systematic review to focus on the
adverse effects of this procedure.
Methods: We will conduct a systematic review of procedure-related adverse effects of ECCO2R systems. A high
sensitivity search strategy will be employed in Cochrane Library, MEDLINE, EMBASE, Web of Science and product
regulatory databases and ongoing trial registers to identify citations. Reference lists of relevant studies and grey
literature will also be searched. Screening of the results will be performed by two reviewers independently using
pre-defined inclusion and exclusion criteria. Clinical trials and observational studies will be included. Data will be
extracted using a purposefully developed extraction form. Appropriateness for statistical pooling of the results
will be determined and carried out if heterogeneity is low to moderate. The GRADE framework will be employed
to grade the overall quality of the evidence.
Discussion: In the UK, the current access to the use of ECCO2R is possible only with special arrangements for
clinical governance, consent and for audit or research. Current evidence on ECCO2R suggests that there are a
number of well-recognised complications which vary greatly across studies. This systematic review will consolidate
the existing knowledge on adverse effects resulting from the use of ECCO2R.
Systematic review registration: PROSPERO CRD42015023503.
Keywords: Extracorporeal membrane carbon dioxide removal, ECCO2R, Adverse effects, Hypercapnic respiratory failure,
Lung transplantation
Background
Indications and current treatment
Acute respiratory failure is a suddenly occurring short-
term life-threatening syndrome, in which the respiratory
system fails in gas exchange function of oxygenation
and/or carbon dioxide elimination, resulting in abnor-
mally low levels of oxygen in the blood [hypoxia, i.e.
arterial oxygen partial pressure (PaO2) <60 mmHg] and/
or abnormally high carbon dioxide levels in the blood
[hypercapnia, i.e. carbon dioxide partial pressure
(PaCO2) >45 mmHg]. Classification depends on the
absence (type 1) or presence (type 2) of hypercapnia.
Type 1 respiratory failure is caused by conditions that
damage the lung tissue, affecting the gas exchange in
the lungs. Type 2 respiratory failure is caused by insuf-
ficient alveolar ventilation of the lungs to expel the
carbon dioxide being produced. A common type of
acute respiratory failure is acute respiratory distress
syndrome (ARDS), which is a disease process resulting
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from a number of conditions including sepsis, pneu-
monia or chest trauma.
Conventional treatment for acute respiratory failure
is mechanical ventilation. However, in some patients,
hypoxia and/or hypercapnia are refractory to mechan-
ical ventilation despite maximal tolerable ventilation
settings (such as inspired oxygen concentration, airway
pressures and tidal volume), which are associated with
ventilation-induced lung injury. In the last few de-
cades, extracorporeal membrane oxygenation (ECMO)
has been occasionally used for carbon dioxide removal
despite the primary purpose being oxygenation. In
recent years, extracorporeal membrane carbon dioxide
removal (ECCO2R) systems have been developed spe-
cifically for carbon dioxide removal in these patients to
provide respiratory support for recovery, or in patients
whose condition has not yet become refractory to facili-
tate protective ventilation, i.e. reduce the ventilation set-
tings to decrease the risk of ventilation-induced lung
injury [1, 2]. ECCO2R systems have also been used as a
bridge to lung transplantation and ventilation weaning
support [3–5]. UK surveys have shown that ECCO2R is
used in a wider range of clinical conditions including
chronic obstructive pulmonary disease (COPD), asthma
and trauma with motivations that range from enabling
lung protective ventilation to compassionate use [6].
The technology
The ECCO2R system was developed from the principle
of ECMO systems by underscoring the importance of
carbon dioxide elimination rather than direct improve-
ment of oxygenation in some patients. The circuit of
the ECCO2R system can be set up in venovenous (VV)
or arteriovenous (AV). For VV setup, a low flow pump
is used to maintain a low extracorporeal flow rate using
only 20–30 % of cardiac output. The ECCO2R system
does not provide complete pulmonary function as it
can achieve only limited oxygenation but provides pre-
dominantly carbon dioxide removal. As neither VV nor
AV circuit allows full cardiopulmonary bypass, the
system provides respiratory function but no cardiac
support [1]. The types of ECCO2R system setup are
summarised in Table 1.
What the procedure involves
The procedure of extracorporeal respiratory support in
the UK is currently restricted to highly specialised inten-
sive care centres. The development of medical devices
specifically to deliver ECCO2R rather than adaptation of
ECMO circuits however allows wider dissemination of
this technology. The initial cannulation is implanted by a
surgeon under local anaesthesia, either percutaneously
under ultrasound or fluoroscopy guidance, or via surgical
cut. The cannulation sites are typically the femoral artery,
femoral vein or internal jugular vein. AV cannulation
needs a dual access system using an artery catheter and a
venous catheter, while VV cannulation applies either a
dual access system using two or three venous catheters, or
a single access with a double lumen catheter. Extracorpor-
eal blood flows via the cannulae continuously through the
oxygenator, a low-resistance synthetic membrane device
where oxygen is supplied as a “sweep gas” to remove CO2
that has diffused out of the blood, before returning to the
patient’s blood circulation [1].
During the extracorporeal support, extracorporeal flow
is monitored by an ultrasound device and can be modified
by clamping the cannulae or adjusting the pump speed.
Regular monitoring of arterial blood gases, cannulation
sites and lower limb perfusion is also required. To reduce
the risk of thrombus formation, the extracorporeal system
is heparin-coated or, during the procedure, continuous
heparin infusion is administered. Extracorporeal respira-
tory support is usually provided for periods ranging from
days up to several weeks, depending on clinical need [2].
Complications
The procedure can have mechanical- and/or patient-
associated complications. Mechanical complications in-
clude circuit disruptions such as oxygenator failure,
pump or heat exchanger malfunction, clots in the circuit
plasma and problems with cannula. Patient-associated
complications include system anticoagulation-related
haemorrhage, cannulation site bleeding, haemolysis,
heparin-induced thrombocytopenia, emboli, distal limb
ischemia from arterial hypoperfusion and distal limb
severe stasis (ischemia and oedema) from venous obs-
truction that may result in amputation [1, 2].
Aim of the systematic review
This systematic review aims to identify adverse effects of
the ECCO2R system for patients with potentially revers-
ible severe acute hypercapnic respiratory failure or being
considered for lung transplantation.
Methods
This systematic review protocol follows the Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses for Protocols (PRISMA-P) reporting guidelines
Table 1 Types of ECCO2R system setup
VV-ECCO2R AV-ECCO2R
Pump Yes No
Extracorporeal flow rate Low Low
Gas exchange Predominantly
CO2 removal
Predominantly
CO2 removal
Cardiac/respiratory support Isolated
respiratory failure
Isolated
respiratory failure
Ventilation Yes Yes
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[7]. A PRISMA-P checklist is included with this manu-
script (see Additional file 1).
Search strategy
Publicly available sources will be searched to identify
studies and systematic reviews on the effectiveness and
safety of ECCO2R. Electronic databases include the fol-
lowing: The Cochrane Library (Wiley) (including CDSR,
DARE, HTA and CENTRAL), Medline (Ovid), Medline
in Process (Ovid), EMBASE (Ovid), Science Citation
Index (Web of Science), Conference Proceedings Cit-
ation Index (Web of Science) and ZETOC (British Li-
brary) will be searched from their commencement to
date. An information specialist will develop the search
strategy using a combination of both indexing and free
text terms. This strategy will then be adapted to be run
across each of the different databases. Other sources will
also be searched including product regulatory databases
and ongoing trial registers. Hand searching of reference
lists of relevant studies will be carried out. Grey litera-
ture will also be searched. The search will be restricted
to articles published in the English language. Literature
search results will be uploaded to and managed using
EndNote X7.0.1 software.
Study selection
The selection criteria described in Table 2 below will be
applied to the citations identified by the literature
search. Two reviewers will independently screen the ti-
tles and abstracts of all retrieved citations and document
the reasons for study exclusion. Where selection criteria
could not be determined from the abstract, full paper of
the citation will be retrieved. Full papers for studies
which deemed potentially relevant by the screening will
be retrieved. Any disagreements will be resolved by dis-
cussion and consensus between the reviewers; if consen-
sus is not reached, a third reviewer will be consulted. If
there is uncertainty whether a full text report meets all
eligibility criteria, the authors will be contacted by email.
In case of no response, the authors will be contacted at
least twice over a 2-week period by email.
Quality assessment
Where appropriate, risk of bias of included studies will
be assessed using the methods introduced in the
Cochrane Handbook for Systematic Reviews of Interven-
tions [8]. Two reviewers will conduct the assessment
independently. Any disagreement will be resolved by
discussion and consensus and if necessary consultation
of a third reviewer.
Data extraction
For each included study, data will be extracted by one
reviewer and checked for accuracy by a second reviewer.
Any disagreements will be resolved by discussion and if
necessary consultation of a third reviewer. The following
data fields will be included: (1) general information
including study ID, author, year, journal, funding source,
study design, setting; (2) recruitment details, sample size,
demographics characteristics (age, gender) and baseline
health data (diagnosis, co-morbidities); (3) type of
ECCO2R system, ECCO2R system setup (i.e. VV and
AV), diameter of cannulae; (4) indication, treatment dur-
ation, follow-up; (5) if applicable, quality assessment and
methods of data analysis; (6) outcomes and definitions
of outcomes. Study authors will not be contacted for
missing data on adverse effects as this would be an
onerous task considering the high volume of potentially
relevant papers on this subject.
Data synthesis and reporting
Studies will be grouped according to the type of study,
indication, type of ECCO2R system, ECCO2R system
setup (i.e. VV and AV) and diameter of cannulae, and
data will be tabulated where appropriate. A narrative
synthesis will be included as it is anticipated that this
review will obtain information from a diverse body of
evidence. Thus, a narrative synthesis may be necessary
to provide potential explanations for contrasting findings
observed in the literature. Appropriateness for statistical
pooling will be determined initially based on an assess-
ment of clinical and methodological heterogeneity of the
studies. Statistical pooling of the results will be carried
Table 2 Inclusion criteria for identification of relevant studies
Characteristic Criteria
Population Patients (including adults and children) with potentially reversible severe acute hypercapnic respiratory failure or
being considered for lung transplantation
Intervention ECCO2R system including VV and AV setups
Comparator Because this systematic review focuses on adverse effects, any comparative and non-comparative studies will be included
Outcome measure Any adverse effects including but not limited to arterial, venous and device thrombus formation; plasma leakage from gas
exchange device; vascular access damage; infections; complications requiring surgery including lower limb amputation;
gas embolism; haemolysis and heparin-induced thrombocytopenia
Study design • Clinical trials and observational studies (including cohort studies, case-control studies, cross-sectional studies and case reports)
• Systematic reviews, meta-analyses and narrative reviews will be included for identification of relevant primary studies
Language Only English language literature will be included
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out using RevMan 5.2, if heterogeneity is low (0 to 40 %)
to moderate (30 to 60 %) and data sufficient [8]. Dichot-
omous data will be expressed as risk ratio with 95 %
confidence interval; mean differences or standardised
mean difference with 95 % confidence interval will be
used for continuous data. Intention-to-treat methods
(i.e. according to group of allocation) will be adopted.
Subgroup analysis and the I2 statistic will be applied to
assess study heterogeneity where applicable. Publication
bias will be assessed using a funnel plot, and sensitivity
analysis on the basis of study quality will be conducted
to explore the robustness of the meta-analysis if the
data allow. Recommendations on testing for funnel plot
asymmetry will be followed to determine whether it is
appropriate to employ funnel plots and which tests to
use based on between-study heterogeneity [9]. The
GRADE framework will be employed to grade the
overall quality of the evidence [10].
The findings from this systematic review will be re-
ported according to the PRISMA harms checklist [11].
Discussion
In June 2012, the National Institute for Health and Care
Excellence (NICE) published Interventional Procedure
Guidance 428 (IPG 428) on the safety and efficacy of
ECCO2R for patients with severe acute respiratory fa-
ilure [12]. The guidance recommends that ECCO2R
should only be used in patients with potentially revers-
ible hypercarbic respiratory failure or those being con-
sidered for lung transplantation; the procedure should
only be undertaken with special arrangements for cli-
nical governance, consent and for audit or research,
because the evidence on the safety of ECCO2R showed a
number of well-recognised complications, and evidence
on its efficacy was limited in quality and quantity. NICE
IPG 428 was based on a rapid review of the literature
with an emphasis on good quality studies, without
consideration for data from small case series and case
reports [12]. The only two systematic reviews to date that
assessed the efficacy and safety of ECCO2R did not spe-
cifically focus on the adverse effects of ECCO2R [13, 14].
In the Fitzgerald et al. review, studies reporting rarely
occurring adverse effects may have been missed as the
authors excluded studies with fewer than 10 patients (e.g.
case report) [13]. Sklar et al. searched only MEDLINE
and EMBASE and did not explore product regulatory
databases that may include unpublished adverse effects
[14]. Moreover, Sklar et al. focused on the use of ECCO2R
for chronic obstructive pulmonary disease only. As previ-
ous systematic reviews have included only specific indica-
tions for ECCO2R [13, 14] and are unlikely to have
identified all relevant reports of adverse effects, further
evidence is required on adverse effects associated with
ECCO2R used for any indication.
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